Skip to main content
Publications
Ahmadizar F, Fortuny J , Cid-Royo A, Plana E , Weinrib R , Garcia Esteban R , Boric K , Yefimenko N, Carreras JJ, Urcheguia A, Correcher-Martinez E, Mira-Iglesias A, Swart KMA, van den Berg JM, Overbeek JA, Villalonos F, Bissacco CA, Newbern C, Praet N, Willame C, Sturkenboom M. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data: methods and results of the first study feasibility assessment . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):189-90. doi: 10.1002/pds.5687
Sultana J, Crisafulli S, Almas M, Antonazzo IC, Baan E, Bartolini C, Bertuccio MP, Bonifazi F, Capuano A, Didio A, Ehrenstein V, Felisi M, Ferrajolo C, Fontana A, Francisca R, Fourrier-Reglat A, Fortuny J , Gini R, Hyeraci G, Hoeve C, Kontogiorgis C, Isgrò V, Lalagkas P, L'Abbate L, Layton D, Landi A, Narduzzi S, Pereira LR, Poulentzas G, Rafaniello C, Roberto G, Scondotto G, Sportiello L, Toma M, Toussi M, Verhamme K, Volpe E, Trifirò G. Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018 . Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413
Fortuny J , von Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, Toft G, Timmer A, Dress J, Blin P, Droz-Perroteau C, Ehrenstein V, Franzoni C , Herings R, Kollhorst B, Moore N, Odsbu I, Perez-Gutthann S , Schink T, Rascher K, Rasouliyan L, Rothman KJ , Saigi-Morgui N , Schaller M, Smits E, Forstner M, Intravenous Iron Consortium, Benichou J, Bircher AJ, Garbe E, Rampton DS, Gutierrez L . Use of intravenous iron and risk of anaphylaxis: a multinational observational post-authorisation safety study in Europe . Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1447-57. doi: 10.1002/pds.5319
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study . Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
Gutierrez L , Bezemer ID, Dress J, Ehrenstein V, Forstner M, Franzoni C , Lassalle R, Linder M, Droz-Perroteau C, Odsbu I, Overbeek JA, Perez-Gutthann S , Pisa FE, Rascher K, Rasouliyan L, Reinold J, Rothman KJ , Saigi-Morgui N , Schaller M, Smits E, Timmer A, Toft G, von Gersdorff G, Fortuny J . Challenges in conducting a multinational European study of severe hypersensitivity reactions among recipients of intravenous iron . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):640. doi: 10.1002/pds.4864
Fortuny J , Gilsenan AW , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
Cainzos-Achirica M, Ruigomez A, MacDonald T, Garcia-Rodriguez L, Fortuny J , Flynn RW, Plana E , Ziemiecki R , Andrews EB, Gilsenan A . Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):331. doi: 10.1002/pds.4864
Margulis AV , Varas-Lorenzo C, Bui CL , McQuay LJ, Ziemiecki R , Reynolds M , Rebordosa C , Pladevall-Vila M , Fortuny J , Rivero-Ferrer E , Plana E , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS) . Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.
McGrath LJ, Rulgomez A, Plana E , Fortuny J , Garcia-Rodriguez L, Rebordosa C , Varas-Lorenzo C, Ziemiecki R , Gilsenan AW , Andrews E. Characteristics of patients prescribed prucalopride versus an active comparator in England, Wales, and Northern Ireland . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):634.
Fortuny J , Kaye JA, Bui CL , Gilsenan AW , Bartsch J , Plana E , McQuay LJ, Calingaert B , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez Gutthan S , Arana A , Margulis AV . Evaluation of free-text comments to validate common cancer diagnoses in the UK CPRD . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58.